greatgenes

How greatgenes works and how reliable it is

greatgenes compares the raw data file from a consumer DNA test with public scientific databases and writes down what those databases say about the variants in your file. This page explains which databases we use, how the report is put together, how much each part can be trusted, and what a DNA chip cannot see.

No guesswork. greatgenes does not use computational “pathogenicity predictors” (such as CADD or SpliceAI) and does not build its own risk models. Each line of the report repeats what a curated database (ClinVar, CPIC, ACMG SF), a published study (GWAS Catalog, PGS Catalog) or a reference resource records — with the source named and its reliability level shown. Built for consumer DNA chips: greatgenes is designed for raw data from 23andMe, AncestryDNA, MyHeritage and FamilyTreeDNA; it reads only the positions a chip measures and says which ones it could not read.

Databases
13 public databases, each named with its licence
Knowledge base built
2026-10-23
ClinVar records
198,495 single-nucleotide variants, of which 195,720 are classed as pathogenic or likely pathogenic (release of 2026-10-04)
Medicines
10 genes by CPIC tables (snapshot 2026-10-13)
Polygenic scores
15 published scores from the PGS Catalog
Traits from GWAS
54 traits and conditions from the GWAS Catalog
Chip versions recognised
11
Where the analysis runs
in your browser; the file is not uploaded

Databases and versions

The knowledge base is built from these databases. The version or date is that of the copy used for the current knowledge base (built 2026-10-23). Licences and terms are on the page Data sources and licences.

SourceWhat we takeVersion / date
ClinVarclinical significance of variantsrelease of 2026-10-04
GWAS Catalogvariant-trait and variant-disease associationsdownloaded 2026-10-12
PGS Catalogpolygenic scores15 scores, each named by its PGS ID
SNPediavariant descriptions and significance (magnitude, repute)downloaded 2026-10-12
Ensembl (1000 Genomes)population allele frequencies (1000 Genomes)GRCh37, downloaded 2026-10-20
CPICpharmacogenetic guidelines: gene, drug, recommendationsnapshot 2026-10-13
DPWGpharmacogenetic guidelines of the Dutch working groupcited per guideline publication
PharmGKB / ClinPGxgene-drug annotations, references in the dictionary and panelclinical annotations of 2025-07-05
ClinGengene-disease validity, actionability, ACMG SF listfile of 2026-10-13
MedlinePlusgene and condition descriptions, inheritance typeversion 2025-06-02
Orphanetrare disease codes and names, inheritance typeexport of 2026-06-23
1000 Genomes Project (IGSR)allele frequencies of pharmacogenes in populationsphase 3, snapshot 2026-10-14
gnomAD v4.1allele frequencies of pharmacogenes in populationsv4.1, snapshot 2026-10-14

Databases are revised and sometimes disagree. The report shows what the databases said in these versions; it does not decide which source is right, and we do not check that the information in the databases is correct.

How the report is organised

The report is built in your browser and goes from the most practical to the most general:

  1. What we read from your file — sex by DNA, a few likely visible traits and the number of positions read, so you can check that the file is yours.
  2. Summary — up to 8 main findings, each with what it means, a next step and a reliability word.
  3. Health-related findings, Carrier status, Lifestyle and nutrition, Traits.
  4. Medications (pharmacogenetics) — how your genes may affect the way your body handles some medicines.
  5. Sensitive results — three collapsed blocks that every report has, whatever the result: Alzheimer’s disease risk (APOE), Parkinson’s disease risk (LRRK2, GBA) and genes of the ACMG secondary-findings list. Some people prefer not to learn these results, so they are not in the Summary and open only if you choose; a block you open is printed, and in the saved file they stay collapsed.
  6. Polygenic scores — only the results that differ from the average are shown openly.
  7. Checked, no signs found — what was looked at and found nothing, including 17 well-known variants listed by name and whether your chip reads them.
  8. About your data, Sources and Not shown — the rest of the matches, which you can download as a full table.

Each finding names its sources. Short quotes from databases are marked as quotes; the rest is retold in our own words.

Finding priority and reliability

In short: a finding ranks higher when a well-reviewed clinical database calls the variant pathogenic, and its reliability word (high, medium, low) shows how well the sources support the link between the variant and the description. Reliability is not the probability of a disease.

How ClinVar review status is used

ClinVar records how thoroughly each classification was reviewed and shows it as stars (ClinVar: review status). greatgenes turns the review status into a weight:

ClinVar review statusClinVar starsWeight in greatgenes
practice guidelinefour (★★★★)4
reviewed by expert panelthree (★★★)4
criteria provided, multiple submitters, no conflictstwo (★★)3
criteria provided, single submitterone (★)2
criteria provided, conflicting classificationsone (★)1
no assertion criteria providednone1

Records with conflicting classifications are not used as pathogenic. Pathogenic records without assertion criteria (no stars) do not raise a finding on their own; the “Not shown” section counts those left in the full table.

Priority

Where our hand-checked dictionary has an entry for the variant and genotype, its category and priority are used.

Reliability score

The score is the weight of the strongest source, plus 0.5 for each further source that agrees, plus 0.5 if another variant in the same gene points the same way. That other variant counts only if it lies more than 100 kb away: closer variants are often inherited together and do not confirm each other. A score of 3.5 or more is high, 2 or more is medium, anything lower is low.

If the chip reports a pathogenic or likely pathogenic variant that is rare (below 0.1 % in the population) or has no known frequency, the finding is not one of the main findings in the Summary, whatever the gene: chips often misread such variants. Its reliability is shown as low — needs confirmation, the finding starts with a note that a clinical confirmation test is needed before any conclusion, and the Summary gives only their number. If the chip reports two copies of such a variant, the report also says that this is a likely chip error.

Medicines (pharmacogenetics)

In short: for 10 genes the report works out the likely gene variants and the metabolizer type using CPIC tables, and retells the CPIC recommendation in plain words. Never change a medicine or dose on your own; show the result to your doctor or pharmacist.

Genes: CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A5, DPYD, G6PD, NUDT15, SLCO1B1, TPMT. The rules are cautious on purpose, so as not to claim more than the chip shows:

How often the named types are right: we compared the report with the consensus genotypes of the CDC GeT-RM reference programme for 147 samples that are also in 1000 Genomes, using files with only the positions of each chip version. For a 23andMe v5 file the report named a metabolizer type or gene function for 66 % of the gene results, and 94.7 % of those were right; for AncestryDNA, array c5.1.0, 51 % and 93.2 %. With every position of the gene tables read, the figures are 80 % and 96.3 %. The rest were reported as not assessed or not determined (“likely …” counts as named). Most wrong types come from variants a chip cannot read (insertions, deletions, gene copies) or from positions missing on the chip; the others are samples where the reference data disagree with each other.

The metabolizer types and recommendations in this section follow CPIC only; recommendations of the Dutch Pharmacogenetics Working Group (DPWG) are not yet included. DPWG is cited in a few single-variant rows of the report (for example, UGT1A1 and irinotecan). Active substance names are used, not brand names.

Polygenic scores and traits

In short: a polygenic score adds up many small effects. It compares you with people of European ancestry; it is not the probability that you will get a disease. A score is used only if your chip covers at least 50 % of it, and the table shows openly only results at least 1 standard deviation from the average.

Published scores (PGS Catalog)

Traits from the GWAS Catalog

Sex-specific results

2 scores and 4 traits apply to one sex only (for example, breast cancer and prostate cancer). Sex is determined from the X and Y chromosome data in the file. If it is known, results for the other sex are not shown. If it cannot be determined, results for both sexes are shown, each marked “for women” or “for men”, with one sentence above the table — use the ones that apply to you.

What is shown openly

Rows where the result is about average, or where the score did not pass the coverage threshold, are folded into “Details” under the table, with a one-line count. The full table, sorted by how far the result is from the average, is always there.

What a DNA chip cannot see

In short: a consumer chip reads between 574,516 and 992,615 chosen positions, depending on the chip version, and makes mistakes on rare variants. If a variant is not in the report, it does not mean you do not have it.

Where your file is processed

In short: the analysis runs in your browser tab. Neither the file, nor any part of it, nor its name, nor the report is sent to the server.

The browser downloads the analysis engine and the part of the knowledge base for your chip model, then reads the file and builds the report on your device. To get these, it sends the server only service requests:

A message from the feedback form reaches the server only if you send one. You can check all of this yourself in the browser’s Network tab: How to check that your file stays with you. The full rules are in the Privacy policy.

What the report is not

greatgenes is an information service. The report records what public databases say about the variants in your file; it is not a diagnosis and not medical advice. Discuss any health finding with a doctor or a clinical geneticist, and do not make medical decisions before a clinical test confirms the result. Never start, stop or change a medicine on your own.

References

  1. ClinVar: review status and star ratings (NCBI).
  2. CPIC guidelines (Clinical Pharmacogenetics Implementation Consortium).
  3. Lambert SA et al. The Polygenic Score Catalog. Nat Genet 2021. doi:10.1038/s41588-021-00783-5
  4. Sollis E et al. The NHGRI-EBI GWAS Catalog. Nucleic Acids Res 2023. doi:10.1093/nar/gkac1010
  5. Choi SW, Mak TS, O’Reilly PF. Tutorial: a guide to performing polygenic risk score analyses. Nat Protoc 2020. doi:10.1038/s41596-020-0353-1
  6. Martin AR et al. Clinical use of current polygenic risk scores may exacerbate health disparities. Nat Genet 2019. doi:10.1038/s41588-019-0379-x
  7. Weedon MN et al. Use of SNP chips to detect rare pathogenic variants: retrospective, population based diagnostic evaluation. BMJ 2021. doi:10.1136/bmj.n214
  8. Tandy-Connor S et al. False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care. Genet Med 2018. PMID 29565420